NNC0472-0147 / Novo Nordisk - LARVOL DELTA

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes (clinicaltrials.gov) - P1; N=36; Completed; Sponsor: Novo Nordisk A/S; Recruiting ➔ Completed; N=68 ➔ 36; Trial completion date: Jan 2021 ➔ Sep 2020; Trial primary completion date: Jan 2021 ➔ Sep 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes (clinicaltrials.gov) - P1; N=68; Recruiting; Sponsor: Novo Nordisk A/S; Trial completion date: Nov 2020 ➔ Feb 2021; Trial primary completion date: Nov 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes (clinicaltrials.gov) - P1; N=68; Recruiting; Sponsor: Novo Nordisk A/S; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes (clinicaltrials.gov) - P1; N=68; Not yet recruiting; Sponsor: Novo Nordisk A/S

Clinical • New P1 trial